Health
Orally administered experimental drug halts SARS-CoV-2 replication, prevents infection – News-Medical.Net
Publishing their work in Nature, scientists at the UNC School of Medicine and UNC Gillings School of Global Public Health found that the orally administered experimental…
Publishing their work in Nature, scientists at the UNC School of Medicine and UNC Gillings School of Global Public Health found that the orally administered experimental drug EIDD-2801 halts SARS-CoV-2 replication and prevents infection of human cells in a new in vivo lab model containing human lung tissue.
Separate phase 2 and 3 clinical trials are ongoing to evaluate EIDD-2801 safety in humans and its effect on viral shedding in COVID-19 patients.
The number of new COVID-19 cases continues to…
-
General23 hours agoWith a deal on Australia’s environmental laws, Murray Watt has cemented his reputation as a ‘fixer’
-
Noosa News19 hours agoSecurity concerns over Chinese-made Yutong fleet dismissed
-
Noosa News19 hours agoEx-Townsville mayor Troy Thompson lied about army service, degrees, and cancer, says CCC
-
Noosa News21 hours agoQueensland’s domestic violence policing and policies are being shaped by lived experience